X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet   (NTPH)

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 1,004.0
Mkt Cap Rs m 166,806
Vol '000 20.3
P/E X 45.1
P/CF X 129.8
EPS (TTM) Rs 22.2
% ch % 0.7
No. of shares m 166.15
% ch week % 3.0
% ch 1-mth % 4.0
% ch 12-mth % 67.0
52 week H/L Rs 1,080.0/495.0
(As on Jul 26, 2017 03:36:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs156358361505877 
Low Rs47134197330424 
Sales per share (Unadj.) Rs162.2163.3168.1210.6223.4 
Earnings per share (Unadj.) Rs17.319.019.122.931.1 
Diluted earnings per shareRs2.93.23.64.36.2 
Cash flow per share (Unadj.) Rs24.324.724.230.040.3 
Dividends per share (Unadj.) Rs2.002.003.004.005.00 
Adj. dividends per shareRs0.340.340.560.761.00 
Dividend yield (eoy) %2.00.81.11.00.8 
Book value per share (Unadj.) Rs108.6125.2152.0170.1219.5 
Adj. book value per shareRs18.421.228.532.143.7 
Shares outstanding (eoy) m28.1528.1531.1531.3733.07 
Bonus/Rights/Conversions  ESOP-PPESOPPA 
Price / Sales ratio x0.61.51.72.02.9 
Avg P/E ratio x5.912.914.618.220.9 
P/CF ratio (eoy) x4.210.011.513.916.1 
Price / Book Value ratio x0.92.01.82.53.0 
Dividend payout %11.610.515.717.516.1 
Avg Mkt Cap Rs m2,8576,9258,69113,10021,504 
No. of employees `000NANANANANA 
Total wages/salary Rs m5896648011,0231,128 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
NATCO PHARMA INCOME DATA
Net Sales Rs m4,5674,5975,2376,6057,389 
Other income Rs m464691124167 
Total revenues Rs m4,6134,6435,3296,7297,556 
Gross profit Rs m9138891,0941,4991,793 
Depreciation Rs m197159159221304 
Interest Rs m130125230263366 
Profit before tax Rs m6326517951,1391,290 
Minority Interest Rs m816116046 
Prior Period Items Rs m-160000 
Extraordinary Inc (Exp) Rs m000-1160 
Tax Rs m137132211364309 
Profit after tax Rs m4875355967191,027 
Gross profit margin %20.019.320.922.724.3 
Effective tax rate %21.620.326.532.023.9 
Net profit margin %10.711.611.410.913.9 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m1,9232,4702,9283,3053,681 
Current liabilities Rs m1,6461,9342,5943,4493,123 
Net working cap to sales %6.111.76.4-2.27.6 
Current ratio x1.21.31.11.01.2 
Inventory Days Days6281778189 
Debtors Days Days4656667259 
Net fixed assets Rs m3,0143,4614,8406,8867,685 
Share capital Rs m282282312314331 
"Free" reserves Rs m2,5363,0054,1384,7686,670 
Net worth Rs m3,0573,5244,7365,3357,259 
Long term debt Rs m5221,2541,3411,378955 
Total assets Rs m5,5437,0739,05210,80411,957 
Interest coverage x5.86.24.55.34.5 
Debt to equity ratio x0.20.40.30.30.1 
Sales to assets ratio x0.80.60.60.60.6 
Return on assets %11.19.39.19.111.7 
Return on equity %15.915.212.613.514.2 
Return on capital %21.116.617.120.120.7 
Exports to sales %21.128.334.242.739.4 
Imports to sales %4.17.07.47.45.7 
Exports (fob) Rs m9641,3011,7902,8172,908 
Imports (cif) Rs m187323388486421 
Fx inflow Rs m9821,3992,1783,2053,445 
Fx outflow Rs m209446570628703 
Net fx Rs m7749531,6082,5772,743 
NATCO PHARMA CASH FLOW
From Operations Rs m 774 370 649 612 1,440 
From Investments Rs m -609 -888 -1,269 -1,071 -1,089 
From Financial Activity Rs m -342 771 628 263 -353 
Net Cashflow Rs m -176 253 8 -196 -1 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   PFIZER  MERCK LTD  FRESENIUS KABI ONCO.  STRIDES SHASUN LTD  LUPIN LTD  

Compare NATCO PHARMA With:   PFIZER  MERCK LTD  FRESENIUS KABI ONCO.  STRIDES SHASUN LTD  LUPIN LTD  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty Reclaims 10,000 Mark; Realty & Metal Stocks Witness Buying(01:30 pm)

After opening the day marginally higher, stock markets in India have continued their momentum. Presently, they are trading near their all-time high levels.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Affordable Housing Gaining Traction(Chart Of The Day)

Jul 15, 2017

Affordable housing is gaining traction amid continuing slowdown in the property market.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS